A. Singla

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Monoclonal antibodies (mAbs) as a class of therapeutic molecules are finding an increasing demand in the biotechnology industry for the treatment of diseases like cancer and multiple sclerosis. A key challenge associated to successful commercialization of mAbs is that from the various physical and chemical instabilities that are inherent to these molecules.(More)
  • 1